EDSA 3.82 Edesa Biotech, Inc.
| Range: | 2.5-6.46 | Vol Avg: | 9695 | Last Div: | 0 | Changes: | -0.13 |
| Beta: | 0.8 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Jun 21 2010 | Empoloyees: | 16 | ||
| CUSIP: | 27966L108 | CIK: | 0001540159 | ISIN: | CA27966L3065 | Country: | CA |
| CEO: | Dr. Pardeep Nijhawan FRCPC, M.D. | Website: | https://www.edesabiotech.com | ||||
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Stock Details
Positive 0.13
Edesa Biotech Announces Upcoming Conference Schedule
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-s...
globenewswire.com·Mon Oct 21 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow